<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="891">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149560</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2021-000823-11</org_study_id>
    <nct_id>NCT05149560</nct_id>
  </id_info>
  <brief_title>Ticagrelor Monotherapy After Stenting</brief_title>
  <acronym>TIMO</acronym>
  <official_title>Ticagrelor Monotherapy After Coronary Stenting in Patients With Acute Myocardial Infarction - A Prospective Single-centre, Single-arm Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study planned to evaluate initial safety of ticagrelor monotherapy after coronary&#xD;
      stenting due to acute myocardial infarction.&#xD;
&#xD;
      The study is a single-centre, single-arm, prospective phase II study 200 patients who undergo&#xD;
      coronary artery stenting due to NSTEMI or STEMI will be included.&#xD;
&#xD;
      Primary endpoint (variable):&#xD;
&#xD;
      The composite of cardiac death, spontaneous myocardial infarction or definite or probable&#xD;
      stent thrombosis within 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot study with 200 subjects undergoing coronary stenting due to NSTEMI or STEMI.&#xD;
&#xD;
      All patients will undergo invasive coronary angiography and clinically indicated Percutaneous&#xD;
      Coronary Intervention (PCI). PCI will be performed using the Xience®-family EES and OCT&#xD;
      guidance using the MLDMAX algorithm (Morphology, Length, Diameter, Medial dissection,&#xD;
      Apposition, Xpansion). Eligibility criteria will be assessed after completion of PCI.&#xD;
&#xD;
      Patients will be given a drug diary to document and as a reminder of the twice daily&#xD;
      ticagrelor administration.&#xD;
&#xD;
      The Data Safety Monitoring Board (DSMB) will continuously review the outcomes for these&#xD;
      patients. After the first 50 patients have been recruited and at least 30 of these patients&#xD;
      have reached 3-month follow-up or had the primary outcome, the DSMB will convene to decide&#xD;
      whether it is safe to proceed with the study. However, the DSMB will strongly consider early&#xD;
      termination of the trial if more than 10 primary endpoint events occur.&#xD;
&#xD;
      Patients may be treated with aspirin prior to coronary angiography, as per local treatment&#xD;
      guidelines. All patients will be followed for 1 year. After one year, all patients will be&#xD;
      treated per the discretion of the treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-centre, single-arm, prospective phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>within 3 months</time_frame>
    <description>The composite of cardiac death, spontaneous myocardial infarction or definite or probable stent thrombosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>within 12 months</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) types 3 or 5 bleeding (time-to-event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis or target vessel myocardial infarction</measure>
    <time_frame>within 12 months</time_frame>
    <description>Definite or probable stent thrombosis or spontaneous target vessel myocardial infarction (time-to-event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>within 12 months</time_frame>
    <description>Any spontaneous myocardial infarction (time-to-event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 12 months</time_frame>
    <description>All-cause mortality (time-to-event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>within 12 months.</time_frame>
    <description>The composite of cardiac death, spontaneous target vessel myocardial infarction or definite or probable stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>at 24 hours</time_frame>
    <description>Platelet reactivity as assessed by the ADP-test (multiplate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>at 3 months</time_frame>
    <description>Platelet reactivity as assessed by the ADP-test (multiplate)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90 mg twice daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>All patients will be prescribed ticagrelor as monotherapy</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women at least 18 years old.&#xD;
&#xD;
          2. Pre- or intra-procedure treatment with ticagrelor.&#xD;
&#xD;
          3. Coronary stenting with an everolimus-eluting stent (EES) from the Xience® family&#xD;
             (Abbott Cardio-vascular®) due to NSTEMI or STEMI, with post-procedure diameter&#xD;
             stenosis &lt;50% and post-procedure Thrombolysis In Myocardial Infarcton (TIMI) flow&#xD;
             grade 3.&#xD;
&#xD;
          4. A total stent length of maximum 60 mm in 1-2 separate vessels.&#xD;
&#xD;
          5. PCI guided by optical coherence tomography (OCT) with MLDMAX workflow&#xD;
&#xD;
          6. Subject has not yet received any post-procedure dose of aspirin or any post-procedure&#xD;
             dose of a different P2Y12 inhibitor than ticagrelor (loading dose or pre-PCI&#xD;
             maintenance dose of aspirin and/or a different P2Y12 inhibitor is allowed)&#xD;
&#xD;
          7. Subject has signed and dated the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned PCI or any planned surgical intervention within the next 6 months.&#xD;
&#xD;
          2. Any indication for chronic anticoagulant therapy&#xD;
&#xD;
          3. Positive COVID-19 antigen or PCR test regardless of symptoms&#xD;
&#xD;
          4. History of definite stent thrombosis&#xD;
&#xD;
          5. Left main coronary artery stenting.&#xD;
&#xD;
          6. Stent thrombosis/restenosis as a culprit lesion.&#xD;
&#xD;
          7. Visible thrombus on angiography after PCI&#xD;
&#xD;
          8. Usage of glycoprotein IIb/IIIa inhibitors&#xD;
&#xD;
          9. Any bifurcation lesion with stenting of both branches.&#xD;
&#xD;
         10. Any treated lesion within an arterial or venous graft.&#xD;
&#xD;
         11. Any additional lesion(s) that need(s) a staged revascularization.&#xD;
&#xD;
         12. Known ejection fraction &lt;30%.&#xD;
&#xD;
         13. Known severe renal insufficiency (eGFR &lt;30 ml/min/1.72 m2).&#xD;
&#xD;
         14. Any life-threatening conditions or medical comorbidity resulting in life expectancy &lt;&#xD;
             12 months.&#xD;
&#xD;
         15. Participation in any investigational study that has not yet reached its primary&#xD;
             endpoint, and for which monotherapy with ticagrelor may affect the primary outcome (as&#xD;
             per the judgement of the investigator).&#xD;
&#xD;
         16. Patients who medicate with a potent CYP3A4 inhibitor (e.g. ketoconazole,&#xD;
             clarithromycin, nefazodone, ritonavir and atazanavir)&#xD;
&#xD;
         17. Pregnancy or woman of childbearing potential who is not sterilized or using a&#xD;
             medically accepted form of contraception.&#xD;
&#xD;
         18. Expected inability (by the investigator) to comply with the protocol&#xD;
&#xD;
         19. Subjects incapable to giving consent personally&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oskar Angerås, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska Universitetssjukhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oskar Angerås, MD, PhD</last_name>
    <phone>+46313427584</phone>
    <email>oskar.angeras@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Björn Redfors, MD, PhD</last_name>
    <phone>+46313427543</phone>
    <email>Bjoern.Redfors@wlab.gu.se</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

